FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (Notable, Notable Labs or the Company), a clinical-stage precision oncology company developing new...
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (€œNotable€ or the €œCompany€), a clinical-stage precision oncology company developing new cancer therapies...
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid...
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (Notable or the Company), a clinical-stage precision oncology company developing a new class of cancer...
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost of drug developmentVolasertib Phase 2 trial initiation...
- PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial - - Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials - - Furthers...
FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (œNotable) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for...
-Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable...
Article Published in November 9th Issue of ASCO™s Journal of Clinical Oncology Precision Oncology (JCO PO) Results highlight PPMP as a tool for identifying most promising drug combinations for...